Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
VISEN Pharmaceuticals ( (HK:2561) ) has shared an announcement.
VISEN Pharmaceuticals announced their interim results for the first half of 2025, highlighting a significant increase in research and development costs and administrative expenses, leading to a larger loss compared to the previous year. Despite the financial losses, the company made progress in its core product, Lonapegsomatropin, by completing regulatory steps and strengthening supply arrangements. They also entered into a strategic collaboration to enhance commercial coverage in China, indicating a focused effort to improve market positioning and product uptake.
More about VISEN Pharmaceuticals
VISEN Pharmaceuticals is a company in the pharmaceutical industry, focusing on developing treatments for pediatric growth hormone deficiency. Their primary product is Lonapegsomatropin, a long-acting growth hormone, and they are actively involved in advancing their drug pipeline and business operations.
Average Trading Volume: 56,278
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$5.24B
See more data about 2561 stock on TipRanks’ Stock Analysis page.